Ardelyx Reports Q1 2026 Results: 38% Revenue Growth and Phase 3 CIC Trial Progress

Ardelyx, Inc. (Nasdaq: ARDX) reported financial results for the first quarter ended March 31, 2026, highlighted by total product revenue of $93.4 million, a 38% increase year-over-year. Revenue for IBSRELA grew 58% to $70.1 million, while XPHOZAH contributed $23.3 million. The company reiterated its full-year 2026 revenue guidance, expecting IBSRELA sales between $410 million and $430 million and XPHOZAH sales between $110 million and $120 million. Ardelyx reported a net loss of $37.6 million ($0.15 per share) and maintained a strong cash position of $238.1 million. On the clinical front, Ardelyx is advancing its pipeline with the Phase 3 ACCEL trial evaluating IBSRELA for chronic idiopathic constipation (CIC). Enrollment for this trial is expected to complete by the end of 2026. Additionally, the company is conducting IND-enabling studies for RDX10531, its next-generation NHE3 inhibitor. Corporate developments included the appointment of a new Chief Medical Officer and Chief Legal Officer, and a debt refinancing that improved capital terms.